CHRS Earnings — Coherus Oncology, Inc. Common Stock Post-ER Performance | BigEarnings
CHRS — Coherus Oncology, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.52
Market Cap$242.2M
P/E1.3
52W Range$0.71 – $2.62
Next Earnings2026-08-06
About Coherus Oncology, Inc. Common Stock
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
